Lisata Therapeutics, Inc.
LSTANASDAQHealthcare● Active
$3.48
+$0.13(+3.88%)
Market Cap$31690237
P/E Ratio—
52W High$5.07
52W Low$1.81
Lisata Therapeutics, Inc. (LSTA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LSTA · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.17M | $1.00M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.15M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.02M | $1.00M | $0.00M | $0.00M | $0.00M |
| Gross Margin %(computed) | 14.12% | 100.00% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $7.95M | $11.33M | $12.73M | $43.46M | $17.58M |
| G&A Expenses | $10.43M | $12.07M | $12.97M | $14.14M | $11.47M |
| Total Operating Expenses | $18.23M | $23.41M | $25.71M | $57.60M | $29.05M |
| Operating Income | ($18.21M) | ($22.41M) | ($25.71M) | ($57.60M) | ($29.05M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.81M | $1.88M | $2.72M | $1.05M | $0.15M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($17.55M) | ($20.78M) | ($23.17M) | ($56.70M) | ($28.97M) |
| Income Tax Expense | ($0.96M) | ($0.80M) | ($2.33M) | ($2.48M) | ($1.51M) |
| Net Income | ($16.59M) | ($19.98M) | ($20.84M) | ($54.23M) | ($27.47M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 |
| Wtd Avg Shares | 8.69M | 8.33M | 8.07M | 5.18M | 3.69M |
| EBITDA | ($18.06M) | ($22.23M) | ($25.52M) | ($57.53M) | ($29.00M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Lisata Therapeutics, Inc. data
About Lisata Therapeutics, Inc. (LSTA) Income Statement
Lisata Therapeutics, Inc. (LSTA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, LSTA reported revenue of $0.00B, gross profit of $0.00B (gross margin 14.12%), and net income of ($0.02B) — a net profit margin of -9756.47%.
Frequently asked questions
LSTA · 4 questionsLisata Therapeutics, Inc. (LSTA) reported revenue of $0.00B for 2025, down 83.0% year-over-year.
LSTA revenueLSTA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09